Join Gilead-Kite surfing into the future of cell therapy. Listen to Nordic researchers discuss perspectives and future promise of CAR-T in haemato-oncology and solid tumours, CAR-T, TCR, CAR-NK, allo-CAR development and the exciting future of immuno-oncology to combat cancer.
Innehållet i podden är skapat av Gilead Sciences Sweden AB, Hemvärnsgatan 9, 171 54 Solna.
All content for The Cell Therapy Podcast is the property of KITE Gilead and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Join Gilead-Kite surfing into the future of cell therapy. Listen to Nordic researchers discuss perspectives and future promise of CAR-T in haemato-oncology and solid tumours, CAR-T, TCR, CAR-NK, allo-CAR development and the exciting future of immuno-oncology to combat cancer.
Innehållet i podden är skapat av Gilead Sciences Sweden AB, Hemvärnsgatan 9, 171 54 Solna.
Chimeric antigen receptor therapy has revolutionized hematology but is there ways we could further improve the immune cells that delivery the therapy?
In this episode we talk to Professor Satu Mustjoki and Dr Olli Dufva and their recent paper ‘Integrated drug profiling and CRISPR screening identify essential pathways for CAR T-cell cytotoxicity’ (Link: https://ashpublications.org/blood/article/135/9/597/429647/Integrated-drug-profiling-and-CRISPR-screening) in Blood. We discuss how T cell responses are modified by drugs that could be used in combination with cellular therapies and how they can both enhance and inhibit CAR T cells functioning. We also get into the molecular mechanisms by which is thought to happen in a number of hematological cancer cells.
You can follow Dr. Olli Dufva and Profesor Mustjoki on twitter at: https://twitter.com/ollidufva and https://twitter.com/hruh_research. Read more about Professor Satu Mustjoki and her group here: https://www2.helsinki.fi/en/researchgroups/hematology-research-unit-helsinki/people
The Cell Therapy Podcast
Join Gilead-Kite surfing into the future of cell therapy. Listen to Nordic researchers discuss perspectives and future promise of CAR-T in haemato-oncology and solid tumours, CAR-T, TCR, CAR-NK, allo-CAR development and the exciting future of immuno-oncology to combat cancer.
Innehållet i podden är skapat av Gilead Sciences Sweden AB, Hemvärnsgatan 9, 171 54 Solna.
